Authors: Eva Tůmová; Michal Vrablík Authors‘ workplace: III. interni klinika – endokrinologie a metabolismu, 1. LF UK a VFN v Praze Published in: AtheroRev 2023; 8(2): 103-108 Category: Reviews
The first step in the successful prevention of atherosclerosis progression in at-risk individuals is their identification and adequate treatment to achieve the desired goals – whether we are talking about blood pressure levels or cholesterol concentrations. It has been repeatedly confirmed that the time during which a patient is exposed to risk factors also plays a very important role, which is why it is essential for GPs to pay more attention to the examination of serum lipid levels and not to hesitate to refer patients to specialised centres so that the start of therapy is not delayed. By far the most effective is early synergistic intervention of arterial hypertension and dyslipidaemia, ideally with a modern fixed drug combination.
arterial hypertension – dyslipidemia – cardiovascular disease – cardiovascular prevention
1. Jozífová M, Cífková R, Lánská V et al. Porovnání léčby hypertenze a rizikového profilu hypertoniků v obecné populaci na specializovaném pracovišti. Cor Vasa 2003; 45(11): 533–541.
2. Strehlow K, Wassmann S, Bohm M et al. Angiotensin AT1 receptor over - -expression in hypercholesterolemia. Ann Med 2000; 32(6): 386–389. Dostupné z DOI: <http://doi 10.3109/07853890008995944>.
3. Stulak JM, Lerman A, Caccitolo JA et al. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis 2001; 154(1): 195–201. Dostupné z DOI: <http://doi 10.1016/ s0021–9150(00)00462–7>.
4. Nickenig G, Harrison G. The AT (1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002; 105(3): 393–396. Dostupné z DOI: <http://doi 10.1161/ hc0302.102618>.
5. Widimiský J, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČHS 2022. Hypertenze – kardiovaskulární prevence 2022; 12(2 Supl): 1–25. Dostupné z WWW: <http://www.hypertension. cz>.
6. Bruining N, de Winter S, Roelandt JR et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis 2009; 20(6): 409–414. Dostupné z DOI: <http://doi 10.1097/MCA.0b013e32832fa9b8>.
7. Visseren FLJ, Mach F, Smulders YM et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2022; 29(1): 5–115: Dostupné z DOI: <http:// doi 10.1093/eurjpc/zwab154>.
8. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 : 165(10): 1147–1152. Dostupné z DOI: <http://doi 10.1001/archinte.165.10.1147>.
9. Hatala R, Pella D, Hatalová K et al. Optimization of blood presure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension. Clin Drug Investig 2012; 32(9): 603–612. Dostupné z DOI: <http://doi 10.1007/BF03261915>.
10. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004 : 25(6): 484–491. Dostupné z DOI: <http://doi 10.1016/j.ehj.2003.11.012>.
11. Yusuf S, Lonn E, Prem P et al. Blood-presure and cholesterol-lowering in persons without cardiovascular disease. N Engl J Med 2016; 374(21): 2032–2043. Dostupné z DOI: <http://doi 10.1056/NEJMoa1600177>.
12. Sleight P. The HOPE Study (Hearth Outcomes Prevention Evaluation). J Renin Angiotensin Aldosteron Syst 2000; 1(1): 18–20. Dostupné z DOI: <http://doi 10.3317/jraas.2000.002>.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
